IP Library Granted Patent US 8,241,885
Granted Patent B2
US 8,241,885 · App. 12/887,692 · Granted Aug 14, 2012

Engineered proteases for affinity purification and processing of fusion proteins

Assignee: University of Maryland, College Park
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,241,885
App. No.
12/887,692
Granted
Aug 14, 2012
Kind
B2
Abstract

The present invention is directed to the identification of a protease prodomain that is capable of binding a corresponding protease with high affinity. The protease prodomain of the present invention is fused to a second protein to form a protease prodomain fusion protein. The presence of a protease prodomain protein in a fusion protein allows for easy and selective purification of the second protein by incubation with the corresponding protease.

Claims (11)

1. An isolated subtilisin variant comprising subtilisin that is altered to bind to a fusion protein that comprises a protein of interest covalently bound by a peptide bond to the C-terminus of a subtilisin prodomain protein, wherein said subtilisin variant comprises a mutation at amino acid position 32 of SEQ ID NO:3, wherein the mutation at position 32 is selected from the group of amino acid substitutions consisting of D32A, D32S, D32V, D32G, and D32T, and the subtilisin variant cleaves the peptide bond between the protein of interest and the prodomain protein of the fusion protein upon incubation of the fusion protein with the subtilisin variant in the presence of a chemical trigger comprising anions.

2. The isolated subtilisin variant of claim 1 , wherein the subtilisin variant further comprises a mutation at one or more of amino acid positions 2, 3, 5, 9, 31, 43, 50, 73, 75-83, 104, 126, 128, 155, 156, 166, 169, 188, 206, 212, 217, 218, 221, 254, and 271 of SEQ ID NO:3.

3. The isolated subtilisin variant of claim 1 , wherein the subtilisin variant further comprises one or more of the following mutations: Q2K, S3C, P5S, S9A, I31 L, K43N, M50F, A73L, a deletion of the amino acids at positions 75-83, E156S, G166S, G169A, S188P, Q206C, N212G, K217L, N218S, T254A, Q271E, Y104A, G128S, L126I, N155L, N155Q, and S221A of SEQ ID NO:3.

4. The isolated subtilisin variant of claim 1 , selected from the following subtilisin mutants of SEQ ID NO:3, subtilisin S189, subtilisin S190, subtilisin S196, subtilisin S197, subtilisin S198, subtilisin S199, and subtilisin S201.

5. A method for purifying a protein of interest comprising:

(i) contacting a fusion protein that comprises a protein of interest covalently bound by a peptide bond to the C-terminus of a subtilisin prodomain protein with a subtilisin variant that is altered to bind to such a fusion protein and comprises a mutation at amino acid position 32 of SEQ ID NO:3 wherein the mutation at amino acid position 32 of SEQ ID NO:3 is selected from the group of amino acid substitutions consisting of D32A, D32S, D32V, D32G, and D32T, whereby the subtilisin variant and the fusion protein form a binding complex;

(ii) incubating the binding complex with a chemical trigger comprising anions sufficient to cleave the protein of interest from the binding complex, wherein the subtilisin variant remains bound to the subtilisin prodomain protein; and

(iii) recovering the protein of interest.

6. The method of claim 5 , wherein the isolated subtilisin variant further comprises a mutation at one or more of the amino acid positions 2, 3, 5, 9, 31, 43, 50, 73, 75-83, 104, 126, 128, 155, 156, 166, 169, 188, 206, 212, 217, 218, 221, 254, and 271 of SEQ ID NO:3.

7. The method of claim 5 , wherein the isolated subtilisin variant further comprises one or more of the following mutations: Q2K, S3C, P5S, S9A, 131 L, K43N, M50F, A73L, a deletion of the amino acids at positions 75-83, E156S, G166S, G169A, S188P, Q206C, N212G, K217L, N218S, T254A, Q271E, Y104A, G128S, L126I, N155L, N155Q, and S221A of SEQ ID NO:3.

8. The method of claim 5 , wherein the protein of interest is selected from among: staphylococcal Protein AB domain; Protein AB mutant A219 ; Streptococcal protein GB domain; Streptococcal protein Ga domain; Protein GB mutant G311; E. coli hypothetical Yab; Bovine α-subunit of transducin; M. thermautotrophicus CDC6; streptavidin; avidin; Taq polymerase; an alkaline phosphatase; a RNase; a DNase; a restriction enzyme; a peroxidase; an endo-1,4-β-glucanase; an endo-1,3-β-glucanase; a chitinase; a glucosidase; an α-glucosidase; a β-glucoronidase; an α-glucoronidase; an amylase; a glucosyl-transferase; a phospho-transferase; a chloramphenicol-acetyl-transferase; a β-lactamase; a luciferase; an esterase; a lipase; a protease; a bacteriocine; an antibiotic; an enzyme inhibitor; a growth factor; a hormone; a receptor; a membrane protein; a nuclear protein; a transcriptional factor; a translational factor; and a nucleic acid modifying enzyme.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jun 13, 2017
From: UNIV OF MARYLAND, COLLEGE PARK
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042776/0200 →
Continuity (3)
Division 10567073
Provisional Application 60493032 · Aug 6, 2003
Related Publication 20110008869A1 · Jan 13, 2011